Physician profile
Geemson Oo
NPI 1841283629
$16,161.56
in general payments reported to CMS, 2019-2025
62 companies · $2,119 in 2025
The $2,119 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,791 · 2020: $1,889 · 2021: $2,975 · 2022: $3,292 · 2023: $2,260 · 2024: $1,836 · 2025: $2,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,208 · Education: $6.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,208.41 |
| Education | $6.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,713.20 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,658.21 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,630.26 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Esperion Therapeutics, INC. | $998.61 | 2020-2023 | Nexletol |
| Sanofi-Aventis U.S. LLC | $928.86 | 2019-2023 | |
| Abbvie INC. | $862.93 | 2020-2024 | |
| Amgen INC. | $816.75 | 2019-2025 | Repatha, Repatha, Otezla |
| Pfizer INC. | $731.78 | 2019-2024 | |
| Lilly USA, LLC | $364.05 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $338.45 | 2019-2024 | Spiriva Respimat, Stiolto Respimat, Jardiance |
| Vanda Pharmaceuticals INC. | $333.55 | 2021-2023 | Hetlioz |
| Corcept Therapeutics | $317.94 | 2024-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $313.75 | 2019-2023 | Xarelto |
| Teva Pharmaceuticals USA, INC. | $312.19 | 2019-2024 | Austedo Xr, Austedo, Ajovy |
| Bayer Healthcare Pharmaceuticals INC. | $306.37 | 2021-2025 |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $234.04 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $216.46 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Otsuka America Pharmaceutical, INC. | $201.36 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $191.68 | 2023-2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $189.63 | 2019-2023 | Seglentis, Livalo |
| E.R. Squibb & Sons, L.L.C. | $183.14 | 2019-2023 | Eliquis |
| Abbott Laboratories | $155.66 | 2024-2025 | Eterna, Octrode |
| Amarin Pharma, INC. | $153.99 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $153.03 | 2021-2024 | |
| Currax Pharmaceuticals LLC | $144.07 | 2021-2025 | Onzetra Xsail, Contrave |
| Grifols USA, LLC | $124.62 | 2023-2025 | Gamunex-C |
| Daiichi Sankyo INC. | $113.68 | 2020-2022 | |
| Boston Scientific Corporation | $110.20 | 2025 | Watchman Flx |
| Baxter Healthcare | $98.69 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Upsher-Smith Laboratories LLC | $88.24 | 2019-2023 | |
| Lundbeck LLC | $80.52 | 2020-2025 | Rexulti |
| Amneal Pharmaceuticals LLC | $79.28 | 2020-2025 | Crexont, Rytary |
| Biogen, INC. | $69.77 | 2021-2023 | Vumerity, Tysabri |
| Shield Therapeutics INC | $64.36 | 2023 | Accrufer |
| Neurocrine Biosciences, INC. | $61.35 | 2023-2024 | Ingrezza, Ongentys |
| Takeda Pharmaceuticals U.S.A., INC. | $55.67 | 2021-2025 | Hyqvia |
| Acadia Pharmaceuticals INC | $52.43 | 2022-2023 | Daybue |
| Sk Life Science, INC. | $52.22 | 2021-2023 | |
| Genzyme Corporation | $47.06 | 2023-2025 | |
| Tanabe Pharma America, INC. | $46.25 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $45.95 | 2023-2025 | Ultomiris, Soliris |
| Idorsia Pharmaceuticals US INC | $42.52 | 2022 | |
| Supernus Pharmaceuticals, INC. | $39.39 | 2019-2020 | |
| Csl Behring | $38.85 | 2021-2024 | Hizentra |
| Biohaven Pharmaceuticals, INC. | $37.44 | 2021 | |
| Mdd US Operations, LLC | $36.21 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $33.32 | 2019 | |
| Banner Life Sciences, LLC | $29.55 | 2022 | |
| Axsome Therapeutics, INC. | $29.09 | 2025 | Symbravo |
| Phathom Pharmaceuticals, INC. | $28.41 | 2024 | Voquezna |
| Tonix Medicines, INC. | $27.81 | 2025 | Zembrace Symtouch |
| Cycle Pharmaceuticals INC | $27.80 | 2025 | Tascenso Odt, Bafiertam |
| Mallinckrodt Hospital Products INC. | $22.72 | 2025 | Acthar |
| Ucb, INC. | $19.25 | 2025 | Nayzilam |
| Hikma Pharmaceuticals USA | $18.45 | 2023 | Mitigare |
| Impel Pharmaceuticals INC. | $15.54 | 2023 | Trudhesa |
| Allergan, INC. | $15.43 | 2021 | |
| Assertio Therapeutics, INC. | $15.04 | 2020 | |
| Neuronetics, INC. | $14.71 | 2022 | |
| Argenx US, INC. | $13.95 | 2025 | Vyvgart Hytrulo |
| Scilex Pharmaceuticals INC. | $12.86 | 2021 | |
| Ge Healthcare | $2.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geemson Oo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.